Evidence map›Paper›PMID 41424776›Full record

ArticleFrontiers in pharmacology2025

Ibogaine's potential role in supporting reward system recovery across diagnostic boundaries.

Mark Nicolas

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Mark NicolasIndependent Researcher, Lampasas, TX, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This article proposes that ibogaine's induction of GDNF, modulation of glutamate and dopamine signaling, and reopening of plasticity represent a unified mechanism capable of restoring reward system fidelity across disorders. This includes addiction, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), and eating disorders, amongst others. These conditions are labelled as distinct and separate yet share disrupted dopaminergic and glutamatergic signaling within the mesocorticolimbic circuitry as a common underlying dysfunction, resulting in maladaptive reinforcement and motivational dysregulation. Ibogaine, a little-known indole alkaloid derived from

Indexed as

addictionglial cell line-derived neurotrophic factor (GDNF)ibogaineneuroplasticityobsessive-compulsive disorder (OCD)post-traumatic stress disorder (PTSD)reward systemtransdiagnostic psychiatry

Identifiers

PMID41424776
PMCPMC12712375

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.